Profile

Susan A. Melin, M.D.Wake Forest Baptist Health

Doctor Rating

4.5 out of 5

142 Ratings
1 Comments

Susan A. Melin, M.D.

Associate Professor,


Clinical Specialties

Breast Cancer

Contact Information

New Patient Appointments: 336-716-WAKE
Returning Patient Appointments: 336-713-5440
Department: 336-716-4464

Insurance Accepted »

Education & Training

  • B.S., University of North Carolina-Chapel Hill , 1977
  • M.D., WFU School of Medicine , 1985
  • Residency, Eastern Virginia Medical Schoo, 1988
  • Fellowship, Univ of NC at Chapel Hill, 1991

Memberships

  • North Carolina Medical Society
  • Am Coll Of Physicians
  • Am Medical Assn
  • Am Soc Of Clinical Oncology

NPI Number

  • 1528042058
Susan A. Melin, M.D.

Doctor Rating

4.5 out of 5

142 Ratings
1 Comments

Susan A. Melin, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Research Interests

cancer/oncogenesis, drugs/therapeutic agents pharm, women's health issues

Contact Information

Academic: 336-716-7975 | Department: 336-716-4464

Recent Publications

Vitolins MZ, Milliron BJ, Hopkins JO, Fulmer A, Lawrence J, Melin S, Case D. Weight loss intervention in survivors of ER/PR-negative breast cancer. Clin Med Insights Womens Health. 2014;7():17-24.

Howard-McNatt M, Lawrence J, Melin SA, Levine EA, Shen P, Stewart JH IV. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer. Am J Surg. 2013;205(4):397-401.

Rugo HS, Serrurier K, Melisko M, Glencer A, Hwang J, D'Agostino R, Hutchens S, Esserman L, Melin S. The Dignicap System to prevent alopecia in women receiving chemotherapy for breast cancer [abstract]. Breast. 2013;22(Suppl 1):S119.

Lawrence JA, Akman SA, Melin SA, Case LD, Schwartz GG. Oral paricalcitol (19-nor-1,25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer: a feasibility trial. Cancer Biol Ther. 2013;14(6):476-480.

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, Thohan V, Jordan J, Melin SA, Torti FM, Little WC, Hamilton CA, Hundley WG. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6(8):877-885.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010;28(1):166-172.

Vitolins M, Lesser GJ, Case LD, Williford SK, Giguere JK, Garino A, Naughton MJ, Lively M, Melin SA, Shaw EG. Self-reported compliance compared to biomarker levels of vitamin E in breast cancer patients participating in a CoQ10 clinical trial [abstract]. J Clin Oncol. 2010;28(15 Suppl):e19524.

Twomley K, D'Agostino R Jr, Lawrence J, Melin S, Ellis LR, Stacey B, Hamilton CA, Torti F, Little W, Hundley W. Early and persistent evidence of subclinical cardiovascular injury after receipt of anthracycline chemotherapy [abstract]. Circulation. 2010;122(21 Suppl):A12766.

Chaosuwannakit N, D'Agostino R Jr, Hamilton CA, Lane KS, Ntim WO, Lawrence J, Melin SA, Ellis LR, Torti FM, Little WC, Hundley WG. Subclinical cardiovascular toxicity of anthracyclines identified with cardiovascular magnetic resonance imaging [abstract]. Circulation. 2009;120(18 Suppl):S299.

Ramanathan RK, Picus J, Raftopoulos H, Bernard S, Lockhart AC, Frenette G, Macdonald J, Melin S, Berg D, Brescia F, et al. A phase II study of milataxel: a novel taxane analogue in previously treated patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008;61(3):453-458.

Miller AA, Case D, Harmon M, Savage P, Lesser G, Hurd D, Melin SA. Phase I study of lenalidomide in solid tumors. J Thorac Oncol. 2007;2(5):445-449.

Kim C, Farmer MR, Yacoub J, Monjazeb A, Levine EA, Aklilu M, Geinsinger [sic] KR [Geisinger KR], Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: mucinous histology is associated with decreased pathologic response rates to neoadjuvant chemoradiation therapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S267.

Monjazeb AM, Farmer MR, Mattern M, Mebea A, Levine EA, Geisinger KR, Mishra G, Melin S, Blackstock AW. Patterns of failure for esophageal cancer patients optimally staged with 18-F-FDG-PET and observed after chemo-radiotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S274.

Blackstock AW, Mornex F, Partensky C, Descos L, Case LD, Melin SA, Levine EA, Mishra G, Limentani SA, Kachnic LA, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer. 2006;95(3):260-265.

Blackstock AW, Aklilu M, Lovato J, Farmer MR, Mishra G, Melin SA, Oaks T, Geisinger K, Levine EA. Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer. Int J Gastrointest Cancer. 2006;37(1):7-14.

Farmer MR, Yacoub J, Aklilu M, Levine EA, Geisinger K, Mishra G, Melin S, Blackstock AW. Tri-modality therapy for esophageal cancer: hemoglobin levels are prognostic for survival but do not predict response to radiochemotherapy [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S269.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Hematology & Oncology

Clinical Specialties

Breast Cancer
Susan A. Melin, M.D.

Susan A. Melin, M.D.

Associate Professor, Hematology & Oncology
Comprehensive Cancer Center
Office of Women in Medicine and Science

Doctor Rating

4.5 out of 5

Susan A. Melin, M.D.142 Ratings
1 Comments

Doctor Ratings

The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Press Ganey Patient Satisfaction Survey

CP concern for questions/worries
4.6
CP efforts to include in decisions
4.6
CP explanations of prob/condition
4.6
CP spoke using clear language
4.7
Friendliness/courtesy of CP
4.7
Likelihood of recommending CP
4.6
Patients' confidence in CP
4.6
Time CP spent with patient
4.5
Wait time at clinic
3.4



Patient Comments

Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.

3/27/2014

Very very good.

Quick Reference

Request an Appointment
New Patients

336-716-WAKE
888-716-WAKE

Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.